<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340062</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria-Tetanus-Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1032</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091032</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Routine childhood vaccination, e.g., for diphtheria, tetanus, and pertussis (DTP), might provide additional protection against SARS-CoV-2 infection. This concept of heterologous immunity was explored in healthy children receiving both DTP and inactivated SARS-CoV-2 vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional study was performed on 154 healthy children aged 6-8 years old in Jakarta, Indonesia. Their vaccination status for the DTP (including a diphtheria-tetanus booster vaccine at 5 years old) and CoronaVac (from 6 years old) vaccines were recorded. Peripheral blood samples were collected from all participants, in which anti-diphtheria toxoid IgG and anti-SARS-CoV-2 S-RBD antibodies and T cell-derived IFN-γ were measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study participants with complete DTP vaccination had significantly higher titers of anti-diphtheria toxoid IgG than the ones without (median = 0.9349 versus 0.2113 IU/mL; <i>p</i> &lt; 0.0001). Upon stratification based on DTP and CoronaVac vaccination statuses, the participants with complete DTP and CoronaVac vaccinations had the highest titer of anti-SARS-CoV-2 S-RBD antibodies (median = 1196 U/mL) and the highest concentration of SARS-CoV-2-specific T cell-derived IFN-γ (median = 560.9 mIU/mL) among all the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Healthy children aged 6-8 years old with complete DTP and CoronaVac vaccinations exhibited stronger SARS-CoV-2-specific T cell immune responses. This might suggest an additional benefit of routine childhood vaccination in generating protection against novel pathogens, presumably via heterologous immunity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santi</LastName><ForeName>Theresia</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6555-4790</Identifier><AffiliationInfo><Affiliation>Doctoral Program in Medical Science, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Juandy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5366-7605</Identifier><AffiliationInfo><Affiliation>Department of Biology, Faculty of Health Sciences, Universitas Pelita Harapan, Tangerang 15811, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mochtar Riady Institute for Nanotechnology, Tangerang 15811, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harahap</LastName><ForeName>Alida Roswita</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Doctoral Program in Medical Science, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werdhani</LastName><ForeName>Retno Asti</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-3280-4295</Identifier><AffiliationInfo><Affiliation>Department of Community Medicine, Cipto Mangunkkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadinegoro</LastName><ForeName>Sri Rezeki S</ForeName><Initials>SRS</Initials><AffiliationInfo><Affiliation>Department of Child Health, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>SahBandar</LastName><ForeName>Ivo Novita</ForeName><Initials>IN</Initials><Identifier Source="ORCID">0000-0001-8375-8463</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, Iwate Medical University, Morioka 028-3694, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prayitno</LastName><ForeName>Ari</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9107-239X</Identifier><AffiliationInfo><Affiliation>Department of Child Health, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munasir</LastName><ForeName>Zakiudin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Child Health, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenplas</LastName><ForeName>Yvan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1862-8651</Identifier><AffiliationInfo><Affiliation>Department of Pediatric, Universitair Ziekenhuis Brussel, 1090 Jette, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegar</LastName><ForeName>Badriul</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Child Health, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NKB-361/UN2.RST/HKP.05.00/2023</GrantID><Agency>University of Indonesia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2-specific immune response</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">diphtheria–tetanus–pertussis vaccine</Keyword><Keyword MajorTopicYN="N">heterologous immunity</Keyword><Keyword MajorTopicYN="N">inactivated COVID-19 vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340062</ArticleId><ArticleId IdType="pmc">PMC11435621</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091032</ArticleId><ArticleId IdType="pii">vaccines12091032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization WHO  COVID-19 Dashboard.  [(accessed on 22 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Barouch D.H. COVID-19 Vaccines—Immunity, Variants, Boosters. N. Engl. J. Med. 2022;387:1011–1020. doi: 10.1056/NEJMra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar M., Shoorekchali J.M., Faraji M.R., Seyyedkolaee M.A., Pagán J.A., Wilson F.A. COVID-19 Vaccine Inequality: A Global Perspective. J. Glob. Health. 2022;12:10–13. doi: 10.7189/jogh.12.03072.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.03072</ArticleId><ArticleId IdType="pmc">PMC9559176</ArticleId><ArticleId IdType="pubmed">36227706</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozzi N., Chinazzi M., Dean N.E., Longini I.M., Halloran M.E., Perra N., Vespignani A. Estimating the Impact of COVID-19 Vaccine Inequities: A Modeling Study. Nat. Commun. 2023;14:3272. doi: 10.1038/s41467-023-39098-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39098-w</ArticleId><ArticleId IdType="pmc">PMC10241610</ArticleId><ArticleId IdType="pubmed">37277329</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman J.B., Lum F.M., Ho P.P.K., Kaminski N., Steinman L. Reduced Development of COVID-19 in Children Reveals Molecular Checkpoints Gating Pathogenesis Illuminating Potential Therapeutics. Proc. Natl. Acad. Sci. USA. 2020;117:24620–24626. doi: 10.1073/pnas.2012358117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012358117</ArticleId><ArticleId IdType="pmc">PMC7547272</ArticleId><ArticleId IdType="pubmed">32883878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Curtis N. Why is COVID-19 less severe in children? A Review of the Proposed Mechanisms Underlying the Age-Related Difference in Severity of SARS-CoV-2 Infections. Arch. Dis. Child. 2021;106:429–439. doi: 10.1136/archdischild-2020-320338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320338</ArticleId><ArticleId IdType="pubmed">33262177</ArticleId></ArticleIdList></Reference><Reference><Citation>Axfors C., Pezzullo A.M., Contopoulos-Ioannidis D.G., Apostolatos A., Ioannidis J.P.A. Differential COVID-19 Infection Rates in Children, Adults, and Elderly: Systematic review and Meta-Analysis of 38 Pre-Vaccination National Seroprevalence Studies. J. Glob. Health. 2023;13:06004. doi: 10.7189/jogh.13.06004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.13.06004</ArticleId><ArticleId IdType="pmc">PMC9850866</ArticleId><ArticleId IdType="pubmed">36655924</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell A.A., Dowell A.C., Moss P., Ladhani S.N. Current State of COVID-19 in Children: 4 Years On. J. Infect. 2024;88:106134. doi: 10.1016/j.jinf.2024.106134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2024.106134</ArticleId><ArticleId IdType="pubmed">38432584</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Jones C.E., Faust S.N. Vaccination against COVID-19—Risks and Benefits in Children. Eur. J. Pediatr. 2024;183:1107–1112. doi: 10.1007/s00431-023-05380-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-023-05380-8</ArticleId><ArticleId IdType="pmc">PMC10950962</ArticleId><ArticleId IdType="pubmed">38169007</ArticleId></ArticleIdList></Reference><Reference><Citation>Castagnoli R., Votto M., Licari A., Brambilla I., Bruno R., Perlini S., Rovida F., Baldanti F., Marseglia G.L. Severe Acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020;174:882–889. doi: 10.1001/jamapediatrics.2020.1467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.1467</ArticleId><ArticleId IdType="pubmed">32320004</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L.R., Rose E.B., Horwitz S.M., Collins J.P., Newhams M.M., Son M.B.F., Newburger J.W., Kleinman L.C., Heidemann S.M., Martin A.A., et al. Multisystem Inflammatory Syndrome in U.S. Child. Adolesc. N. Engl. J. Med. 2020;383:334–346. doi: 10.1056/NEJMoa2021680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021680</ArticleId><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L., Van Paemel R., Haerynck F. Multisystem Inflammatory Syndrome in Children Related to COVID-19: A Systematic Review. Eur. J. Pediatr. 2021;180:2019–2034. doi: 10.1007/s00431-021-03993-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pmc">PMC7890544</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pudjiadi A.H., Putri N.D., Sjakti H.A., Yanuarso P.B., Gunardi H., Roeslani R.D., Pasaribu A.D., Nurmalia L.D., Sambo C.M., Ugrasena I.D.G., et al. Pediatric COVID-19: Report From Indonesian Pediatric Society Data Registry. Front. Pediatr. 2021;9:716898. doi: 10.3389/fped.2021.716898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.716898</ArticleId><ArticleId IdType="pmc">PMC8495320</ArticleId><ArticleId IdType="pubmed">34631619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachega J.B., Sam-Agudu N.A., MacHekano R.N., Rabie H., Van Der Zalm M.M., Redfern A., Dramowski A., O’Connell N., Pipo M.T., Tshilanda M.B., et al. Assessment of Clinical Outcomes among Children and Adolescents Hospitalized with COVID-19 in 6 Sub-Saharan African Countries. JAMA Pediatr. 2022;176:E216436. doi: 10.1001/jamapediatrics.2021.6436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.6436</ArticleId><ArticleId IdType="pmc">PMC8771438</ArticleId><ArticleId IdType="pubmed">35044430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Prado E., Izquierdo-Condoy J.S., Fernandez-Naranjo R., Vasconez J., Dávila Rosero M.G., Revelo-Bastidas D., Herrería-Quiñonez D., Rubio-Neira M. The Deadly Impact of COVID-19 among Children from Latin America: The Case of Ecuador. Front. Pediatr. 2023;11:1060311. doi: 10.3389/fped.2023.1060311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2023.1060311</ArticleId><ArticleId IdType="pmc">PMC10160383</ArticleId><ArticleId IdType="pubmed">37152328</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Valdez L., Richardson V.L., Bautista-Márquez A., Camacho Franco M.A., Cruz Cruz V., Hernández Ávila M. Three Years of COVID-19 in Children That Attend the Mexican Social Security Institute’s 1350 Child Day-Care Centers, 2020–2023. Front. Pediatr. 2023;11:1292629. doi: 10.3389/fped.2023.1292629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2023.1292629</ArticleId><ArticleId IdType="pmc">PMC10795536</ArticleId><ArticleId IdType="pubmed">38239590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni D., Ismail N.F., Zhu F., Wang X., del Carmen Morales G., Srivastava A., Allen K.E., Spinardi J., Rahman A.E., Kyaw M.H., et al. Epidemiology and Clinical Features of SARS-CoV-2 Infection in Children and Adolescents in the Pre-Omicron Era: A Global Systematic Review and Meta-Analysis. J. Glob. Health. 2024;14:05003. doi: 10.7189/jogh.14.05003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.14.05003</ArticleId><ArticleId IdType="pmc">PMC10902805</ArticleId><ArticleId IdType="pubmed">38419461</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker L.M., Boucau J., Regan J., Choudhary M.C., Burns M.D., Young N., Farkas E.J., Davis J.P., Moschovis P.P., Bernard Kinane T., et al. Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J. Infect. Dis. 2021;224:1821–1829. doi: 10.1093/infdis/jiab509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab509</ArticleId><ArticleId IdType="pmc">PMC8643403</ArticleId><ArticleId IdType="pubmed">34647601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Zhang P., Liang Y., Du B., Li L., Yu Z., Wang H., Wang Q., Zhang X., Zhang W. A Systematic Review of Current Status and Challenges of Vaccinating Children against SARS-CoV-2. J. Infect. Public Health. 2022;15:1212–1224. doi: 10.1016/j.jiph.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9557115</ArticleId><ArticleId IdType="pubmed">36257126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P., Kang L.-Y., Liu J., Liu M. Immunogenicity, Efectiveness, and Safety of COVID-19 Vaccines among Children and Adolescents Aged 2–18 Years: An Updated Systematic Review and Meta-analysis. World J. Pediatr. 2023;19:1041–1054. doi: 10.1007/s12519-022-00680-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-022-00680-9</ArticleId><ArticleId IdType="pmc">PMC9890438</ArticleId><ArticleId IdType="pubmed">36723827</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D., Rosa Duque J.S., Yip K.M., So H.K., Wong W.H.S., Lau Y.L. Effectiveness of BNT162b2 and CoronaVac in Children and Adolescents against SARS-CoV-2 Infection during Omicron BA.2 Wave in Hong Kong. Commun. Med. 2023;3:3. doi: 10.1038/s43856-022-00233-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-022-00233-1</ArticleId><ArticleId IdType="pmc">PMC9813885</ArticleId><ArticleId IdType="pubmed">36604522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladhani S.N. COVID-19 Vaccination for Children Aged 5–11 Years. Lancet. 2022;400:74–76. doi: 10.1016/S0140-6736(22)01245-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01245-4</ArticleId><ArticleId IdType="pmc">PMC9246472</ArticleId><ArticleId IdType="pubmed">35780800</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechotta V., Siemens W., Thielemann I., Toews M., Koch J., Vygen-Bonnet S., Kothari K., Grummich K., Braun C., Kapp P., et al. Safety and Effectiveness of Vaccines against COVID-19 in Children Aged 5–11 Years: A Systematic Review and Meta-Analysis. Lancet Child Adolesc. Health. 2023;7:379–391. doi: 10.1016/S2352-4642(23)00078-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00078-0</ArticleId><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="pubmed">37084750</ArticleId></ArticleIdList></Reference><Reference><Citation>da Fonseca Lima E.J., Leite R.D. COVID-19 Vaccination in Children: A Public Health Priority. J. Pediatr. (Rio. J.) 2023;99:S28–S36. doi: 10.1016/j.jped.2022.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jped.2022.11.006</ArticleId><ArticleId IdType="pmc">PMC9767816</ArticleId><ArticleId IdType="pubmed">36564007</ArticleId></ArticleIdList></Reference><Reference><Citation>Copland E., Patone M., Saatci D., Handunnetthi L., Hirst J., Hunt D.P.J., Mills N.L., Moss P., Sheikh A., Coupland C.A.C., et al. Safety Outcomes Following COVID-19 Vaccination and Infection in 5.1 Million Children in England. Nat. Commun. 2024;15:3822. doi: 10.1038/s41467-024-47745-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47745-z</ArticleId><ArticleId IdType="pmc">PMC11130197</ArticleId><ArticleId IdType="pubmed">38802362</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B., Song Y., Li C., Yang W., Ma Q., Jiang Z., Li M., Lian X., Jiao W., Wang L., et al. Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Double-Blind, Randomised, Controlled, Phase 1/2 Clinical Trial. Lancet Infect. Dis. 2021;21:1645–1653. doi: 10.1016/S1473-3099(21)00319-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00319-4</ArticleId><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D.S., Bao X.P., Zhu J.J., Zheng W.J., Sun L.X. Safety of an Inactivated COVID-19 Vaccine (CoronaVac) in Children Aged 7-14 Years in Taizhou, China. Diagn. Microbiol. Infect. Dis. 2024;109:116253. doi: 10.1016/j.diagmicrobio.2024.116253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2024.116253</ArticleId><ArticleId IdType="pubmed">38507964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak B.O., Eun B.W. COVID-19 in Immunocompromised Children and Adolescents. Clin. Exp. Pediatr. 2023;66:182–189. doi: 10.3345/cep.2022.00878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/cep.2022.00878</ArticleId><ArticleId IdType="pmc">PMC10167403</ArticleId><ArticleId IdType="pubmed">37070297</ArticleId></ArticleIdList></Reference><Reference><Citation>Poparn H., Srichumpuang C., Sosothikul D., Jantarabenjakul W., Lauhasurayotin S., Techavichit P., Chiengthong K., Poovorapan Y. Immune Response after 2 Doses of BNT162b2 MRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. Asian Pac. J. Cancer Prev. 2022;23:2049–2055. doi: 10.31557/APJCP.2022.23.6.2049.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2022.23.6.2049</ArticleId><ArticleId IdType="pmc">PMC9587837</ArticleId><ArticleId IdType="pubmed">35763647</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D., Mu X., Duque J.S.R., Cheng S.M.S., Wang M., Zhang W., Zhang Y., Tam I.Y.S., Lee T.S.S., Lam J.H.Y., et al. Safety and Immunogenicity of 3 Doses of BNT162b2 and CoronaVac in Children and Adults with Inborn Errors of Immunity. Front. Immunol. 2022;13:982155. doi: 10.3389/fimmu.2022.982155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.982155</ArticleId><ArticleId IdType="pmc">PMC9530261</ArticleId><ArticleId IdType="pubmed">36203563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K., Park S., Kim E.Y., Koyanagi A., Jacob L., Yon D.K., Lee S.W., Kim M.S., Radua J., Elena D., et al. Immunogenicity of COVID-19 Vaccines in Patients with Diverse Health Conditions: A Comprehensive Systematic Review. J. Med. Virol. 2022;94:4144–4155. doi: 10.1002/jmv.27828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27828</ArticleId><ArticleId IdType="pmc">PMC9347877</ArticleId><ArticleId IdType="pubmed">35567325</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt K.L.J., Dautzenberg N.M.M., Hoogerbrugge P.M., Lindemans C.A., Nierkens S., Smits G., Van Binnendijk R.S., Bont L.J., Tissing W.J.E. Immune Response Following BNT162b2 MRNA COVID-19 Vaccination in Pediatric Cancer Patients. Cancers. 2023;15:2562. doi: 10.3390/cancers15092562.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15092562</ArticleId><ArticleId IdType="pmc">PMC10177402</ArticleId><ArticleId IdType="pubmed">37174028</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji K., Funaki T., Yamada M., Mikami M., Miyake K., Ueno S., Tao C., Myojin S., Aiba H., Matsui T., et al. Safety of and Antibody Response to the BNT162b2 COVID-19 Vaccine in Adolescents and Young Adults with Underlying Disease. J. Infect. Chemother. 2023;29:61–66. doi: 10.1016/j.jiac.2022.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.09.013</ArticleId><ArticleId IdType="pmc">PMC9490955</ArticleId><ArticleId IdType="pubmed">36152928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zendt M., Bustos Carrillo F.A., Kelly S., Saturday T., DeGrange M., Ginigeme A., Wu L., Callier V., Ortega-Villa A., Faust M., et al. Characterization of the Antispike IgG Immune Response to COVID-19 Vaccines in People with a Wide Variety of Immunodeficiencies. Sci. Adv. 2023;9:eadh3150. doi: 10.1126/sciadv.adh3150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adh3150</ArticleId><ArticleId IdType="pmc">PMC10569702</ArticleId><ArticleId IdType="pubmed">37824621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartantri Y., Debora J., Widyatmoko L., Giwangkancana G., Suryadinata H., Susandi E., Hutajulu E., Hakiman A.P.A., Pusparini Y., Alisjahbana B. Clinical and Treatment Factors Associated with the Mortality of COVID-19 Patients Admitted to a Referral Hospital in Indonesia. Lancet Reg. Health. 2023;11:100167. doi: 10.1016/j.lansea.2023.100167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2023.100167</ArticleId><ArticleId IdType="pmc">PMC9910028</ArticleId><ArticleId IdType="pubmed">36785545</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi T., Hegar B., Munasir Z., Prayitno A., Werdhani R.A., Bandar I.N.S., Jo J., Uswa R., Widia R., Vandenplas Y. Factors Associated with Parental Intention to Vaccinate Their Preschool Children against COVID-19: A Cross-Sectional Survey in Urban Area of Jakarta, Indonesia. Clin. Exp. Vaccine Res. 2023;12:240–248. doi: 10.7774/cevr.2023.12.3.240.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2023.12.3.240</ArticleId><ArticleId IdType="pmc">PMC10435772</ArticleId><ArticleId IdType="pubmed">37599811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health Republic of Indonesia Vaksinasi COVID-19 Nasional.  [(accessed on 24 August 2024)].  Available online:  https://vaksin.kemkes.go.id/#/vaccines.</Citation></Reference><Reference><Citation>Widianto S. Indonesia to Start Vaccinating Children Aged 6–11 against COVID-19.  [(accessed on 22 June 2024)].  Available online:  https://www.reuters.com/business/healthcare-pharmaceuticals/indonesia-start-vaccinating-children-aged-6-11-against-covid-19-2021-12-13/</Citation></Reference><Reference><Citation>Suhenda D. COVID-19 Vaccine Shortages Reported across Country.  [(accessed on 22 June 2024)].  Available online:  https://www.thejakartapost.com/indonesia/2022/10/21/covid-19-vaccine-shortages-reported-across-country.html.</Citation></Reference><Reference><Citation>Messina N.L., Zimmermann P., Curtis N. The Impact of Vaccines on Heterologous Adaptive Immunity. Clin. Microbiol. Infect. 2019;25:1484–1493. doi: 10.1016/j.cmi.2019.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.02.016</ArticleId><ArticleId IdType="pubmed">30797062</ArticleId></ArticleIdList></Reference><Reference><Citation>Reche P.A. Potential Cross-Reactive Immunity to SARS-CoV-2 from Common Human Pathogens and Vaccines. Front. Immunol. 2020;11:586984. doi: 10.3389/fimmu.2020.586984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.586984</ArticleId><ArticleId IdType="pmc">PMC7596387</ArticleId><ArticleId IdType="pubmed">33178220</ArticleId></ArticleIdList></Reference><Reference><Citation>Monereo-Sánchez J., Luykx J.J., Pinzón-Espinosa J., Richard G., Motazedi E., Westlye L.T., Andreassen O.A., van der Meer D. Diphtheria And Tetanus Vaccination History Is Associated with Lower Odds of COVID-19 Hospitalization. Front. Immunol. 2021;12:749264. doi: 10.3389/fimmu.2021.749264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.749264</ArticleId><ArticleId IdType="pmc">PMC8529993</ArticleId><ArticleId IdType="pubmed">34691063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson L., Adkins E., Karyanti M.R., Ong-Lim A., Shenoy B., Huoi C., Vargas-Zambrano J.C. What Is the True Burden of Diphtheria, Tetanus, Pertussis and Poliovirus in Children Aged 3–18 Years in Asia? A Systematic Literature Review. Int. J. Infect. Dis. 2022;117:116–129. doi: 10.1016/j.ijid.2022.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.01.045</ArticleId><ArticleId IdType="pubmed">35077880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yosephine P. Vaccine Preventable Diseases, Current Status, Outbreak and Mitigation. In: Gunardi S.R.H., Handryastuti H., Kaswandhani S., Raihan N., editors. Proceeding Book Childhood Immunization Update 2023; Hadinegoro. Badan Penerbit Ikatan Dokter Anak Indonesia; Jakarta, Indonesia: 2023.</Citation></Reference><Reference><Citation>World Health Organization Diphtheria Vaccine: WHO Position Paper, August 2017. Wkly. Epidemiol. Rec. 2017;92:417–436.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zasada A.A., Rastawicki W., Śmietańska K., Rokosz N., Jagielski M. Comparison of Seven Commercial Enzyme-Linked Immunosorbent Assays for the Detection of Anti-Diphtheria Toxin Antibodies. Eur. J. Clin. Microbiol. Infect. Dis. 2013;32:891–897. doi: 10.1007/s10096-013-1823-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-013-1823-y</ArticleId><ArticleId IdType="pubmed">23354678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J., Sanjaya A., Pinontoan R., Aruan M., Wahyuni R.M., Viktaria V. Assessment on Anti-SARS-CoV-2 Receptor-Binding Domain Antibodies among CoronaVac-Vaccinated Indonesian Adults. Clin. Exp. Vaccine Res. 2022;11:116. doi: 10.7774/cevr.2022.11.1.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2022.11.1.116</ArticleId><ArticleId IdType="pmc">PMC8844676</ArticleId><ArticleId IdType="pubmed">35223672</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad Albichr I., Mzougui S., Devresse A., Georgery H., Goffin E., Kanaan N., Yombi J.C., Belkhir L., De Greef J., Scohy A., et al. Evaluation of a Commercial Interferon-γ Release Assay for the Detection of SARS-CoV-2 T-Cell Response after Vaccination. Heliyon. 2023;9:e17186. doi: 10.1016/j.heliyon.2023.e17186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e17186</ArticleId><ArticleId IdType="pmc">PMC10256590</ArticleId><ArticleId IdType="pubmed">37325456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappaport E.B. Identifying and Evaluating the Metabolic Syndrome in Children and Adolescents. Ethn. Dis. 2007;17:S4-1-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17985723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.T., Lim J.M.E., Le Bert N., Kunasegaran K., Chia A., Qui M.D.C., Tan N., Chia W.N., de Alwis R., Ying D., et al. Rapid Measurement of SARS-CoV-2 Spike T Cells in whole Blood from Vaccinated and Naturally Infected Individuals. J. Clin. Investig. 2021;131:e152379. doi: 10.1172/JCI152379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI152379</ArticleId><ArticleId IdType="pmc">PMC8409582</ArticleId><ArticleId IdType="pubmed">34623327</ArticleId></ArticleIdList></Reference><Reference><Citation>Indonesian Pediatric Society Proceeding Book Childhood Immunization Update 2023. IDAI; Jakarta, Indonesia: 2023.</Citation></Reference><Reference><Citation>Harapan H., Anwar S., Dimiati H., Hayati Z., Mudatsir M. Diphtheria Outbreak in Indonesia, 2017: An Outbreak of an Ancient and Vaccine-Preventable Disease in the Third Millennium. Clin. Epidemiol. Glob. Health. 2019;7:261–262. doi: 10.1016/j.cegh.2018.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2018.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Itiakorit H., Sathyamoorthi A., O’Brien B.E., Nguyen D. COVID-19 Impact on Disparity in Childhood Immunization in Low- and Middle-Income Countries Through the Lens of Historical Pandemics. Curr. Trop. Med. Rep. 2022;9:225–233. doi: 10.1007/s40475-022-00273-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40475-022-00273-6</ArticleId><ArticleId IdType="pmc">PMC9760533</ArticleId><ArticleId IdType="pubmed">36569790</ArticleId></ArticleIdList></Reference><Reference><Citation>Arguni E., Karyanti M.R., Satari H.I., Hadinegoro S.R. Diphtheria Outbreak in Jakarta and Tangerang, Indonesia: Epidemiological and Clinical Predictor Factors for Death. PLoS ONE. 2021;16:e0246301. doi: 10.1371/journal.pone.0246301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246301</ArticleId><ArticleId IdType="pmc">PMC7861411</ArticleId><ArticleId IdType="pubmed">33539453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunarno S., Sofiah S.N., Amalia N., Hartoyo Y., Rizki A., Puspandari N., Saraswati R.D., Febriyana D., Febrianti T., Susanti I., et al. Laboratory and Epidemiology Data of Pertussis Cases and Close Contacts: A 5-Year Case-Based Surveillance of Pertussis in Indonesia, 2016–2020. PLoS ONE. 2022;17:e0266033. doi: 10.1371/journal.pone.0266033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266033</ArticleId><ArticleId IdType="pmc">PMC9020744</ArticleId><ArticleId IdType="pubmed">35442946</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter E.B., Talaat K.R., Sabharwal C., Gurtman A., Lockhart S., Paulsen G.C., Barnett E.D., Muñoz F.M., Maldonado Y., Pahud B.A., et al. Evaluation of the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022;386:35–46. doi: 10.1056/NEJMoa2116298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., Wu Q., Pan H., Li M., Yang J., Wang L., Wu Z., Jiang D., Deng X., Chu K., et al. Immunogenicity and Safety of a Third Dose of CoronaVac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results from Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials. Lancet Infect. Dis. 2022;22:483–495. doi: 10.1016/S1473-3099(21)00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J.M.E., Hang S.K., Hariharaputran S., Chia A., Tan N., Lee E.S., Chng E., Lim P.L., Young B.E., Lye D.C., et al. A Comparative Characterization of SARS-CoV-2-Specific T Cells Induced by MRNA or Inactive Virus COVID-19 Vaccines. Cell Rep. Med. 2022;3:100793. doi: 10.1016/j.xcrm.2022.100793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100793</ArticleId><ArticleId IdType="pmc">PMC9534788</ArticleId><ArticleId IdType="pubmed">36257326</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Ying L., Wang J., Xia J., Zhang Y., Mao H., Zhang R., Zang R., Le Z., Shu Q., et al. Non-Spike and Spike-Specific Memory T Cell Responses after the Third Dose of Inactivated COVID-19 Vaccine. Front. Immunol. 2023;14:1139620. doi: 10.3389/fimmu.2023.1139620.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1139620</ArticleId><ArticleId IdType="pmc">PMC10126277</ArticleId><ArticleId IdType="pubmed">37114058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti A., Le Bert N., Tan A.T. SARS-CoV-2-Specific T Cells in the Changing Landscape of the COVID-19 Pandemic. Immunity. 2022;55:1764–1778. doi: 10.1016/j.immuni.2022.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.08.008</ArticleId><ArticleId IdType="pmc">PMC9385766</ArticleId><ArticleId IdType="pubmed">36049482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y., Kang A.Y.H., Tay C.J.X., Li H.E., Elyana N., Tan C.W., Yap W.C., Lim J.M.E., Le Bert N., Chan K.R., et al. Correlates of Protection against Symptomatic SARS-CoV-2 in Vaccinated Children. Nat. Med. 2024;30:1373–1383. doi: 10.1038/s41591-024-02962-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02962-3</ArticleId><ArticleId IdType="pmc">PMC11164684</ArticleId><ArticleId IdType="pubmed">38689059</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi T., Sungono V., Kamarga L., De Samakto B., Hidayat F., Hidayat F.K., Satolom M., Permana A., Yusuf I., Suriapranata I.M., et al. Heterologous Prime-Boost with the MRNA-1273 Vaccine among CoronaVac-Vaccinated Healthcare Workers in Indonesia. Clin. Exp. Vaccine Res. 2022;11:209–216. doi: 10.7774/cevr.2022.11.2.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2022.11.2.209</ArticleId><ArticleId IdType="pmc">PMC9200645</ArticleId><ArticleId IdType="pubmed">35799870</ArticleId></ArticleIdList></Reference><Reference><Citation>Barin B., Kasap U., Selçuk F., Volkan E., Uluçkan Ö. Comparison of SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG Antibody Responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 Vaccines, and a Single Booster Dose: A Prospective, Longitudinal Population-Based Study. Lancet Microbe. 2022;3:e274–e283. doi: 10.1016/S2666-5247(21)00305-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00305-0</ArticleId><ArticleId IdType="pmc">PMC8828370</ArticleId><ArticleId IdType="pubmed">35165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens S.A.C., Weckx L., Clemens R., Mendes A.V.A., Souza A.R., Silveira M.B.V., da Guarda S.N.F., de Nobrega M.M., de Pinto M.I.M., Gonzalez I.G.S., et al. Heterologous versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single Blind, Randomised Study. Lancet. 2022;399:521–529. doi: 10.1016/S0140-6736(22)00094-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00094-0</ArticleId><ArticleId IdType="pmc">PMC8782575</ArticleId><ArticleId IdType="pubmed">35074136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadlyana E., Setiabudi D., Kartasasmita C.B., Putri N.D., Rezeki Hadinegoro S., Mulholland K., Sofiatin Y., Suryadinata H., Hartantri Y., Sukandar H., et al. Immunogenicity and Safety in Healthy Adults of Full Dose versus Half Doses of COVID-19 Vaccine (ChAdOx1-S or BNT162b2) or Full-Dose CoronaVac Administered as a Booster Dose after Priming with CoronaVac: A Randomised, Observer-Masked, Controlled Trial in I. Lancet Infect. Dis. 2023;23:545–555. doi: 10.1016/S1473-3099(22)00800-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00800-3</ArticleId><ArticleId IdType="pubmed">36640798</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauré D., O’Ryan M., Torres J.P., Zuñiga M., Soto-Rifo R., Valiente-Echeverría F., Gaete-Argel A., Neira I., Saavedra V., Acevedo M.L., et al. COVID-19 Lateral Flow IgG Seropositivity and Serum Neutralising Antibody Responses after Primary and Booster Vaccinations in Chile: A Cross-Sectional Study. Lancet Microbe. 2023;4:e149–e158. doi: 10.1016/S2666-5247(22)00290-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00290-7</ArticleId><ArticleId IdType="pmc">PMC9883018</ArticleId><ArticleId IdType="pubmed">36716754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J.F. Systematic Review of COVID-19 in Children Shows Milder Cases and a Better Prognosis than Adults. Acta Paediatr. Int. J. Paediatr. 2020;109:1088–1095. doi: 10.1111/apa.15270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15270</ArticleId><ArticleId IdType="pmc">PMC7228328</ArticleId><ArticleId IdType="pubmed">32202343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysore V., Cullere X., Settles M.L., Ji X., Kattan M.W., Desjardins M., Durbin-Johnson B., Gilboa T., Baden L.R., Walt D.R., et al. Protective Heterologous T Cell Immunity in COVID-19 Induced by the Trivalent MMR and Tdap Vaccine Antigens. Med. 2021;2:1050–1071.e7. doi: 10.1016/j.medj.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8363466</ArticleId><ArticleId IdType="pubmed">34414383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski C., Puranik A., Bandi H., Venkatakrishnan A.J., Agarwal V., Kennedy R., O’Horo J.C., Gores G.J., Williams A.W., Halamka J., et al. Exploratory Analysis of Immunization Records Highlights Decreased SARS-CoV-2 Rates in Individuals with Recent Non-COVID-19 Vaccinations. Sci. Rep. 2021;11:4741. doi: 10.1038/s41598-021-83641-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83641-y</ArticleId><ArticleId IdType="pmc">PMC7910541</ArticleId><ArticleId IdType="pubmed">33637783</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad-Boubaker S., Othman H., Touati R., Ayouni K., Lakhal M., Ben Mustapha I., Ghedira K., Kharrat M., Triki H. In Silico Comparative Study of SARS-CoV-2 Proteins and Antigenic Proteins in BCG, OPV, MMR and Other Vaccines: Evidence of a Possible Putative Protective Effect. BMC Bioinform. 2021;22:163. doi: 10.1186/s12859-021-04045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-021-04045-3</ArticleId><ArticleId IdType="pmc">PMC7995392</ArticleId><ArticleId IdType="pubmed">33771096</ArticleId></ArticleIdList></Reference><Reference><Citation>Balz K., Trassl L., Härtel V., Nelson P.P., Skevaki C. Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development. Front. Immunol. 2020;11:513. doi: 10.3389/fimmu.2020.00513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00513</ArticleId><ArticleId IdType="pmc">PMC7137989</ArticleId><ArticleId IdType="pubmed">32296430</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil A., Kenney L.L., Mishra R., Watkin L.B., Aslan N., Selin L.K. Vaccination and Heterologous Immunity: Educating the Immune System. Trans. R. Soc. Trop. Med. Hyg. 2014;109:62–69. doi: 10.1093/trstmh/tru198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/tru198</ArticleId><ArticleId IdType="pmc">PMC4351360</ArticleId><ArticleId IdType="pubmed">25573110</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggenhuizen P.J., Ng B.H., Chang J., Cheong R.M.Y., Yellapragada A., Wong W.Y., Ting Y.T., Monk J.A., Gan P.Y., Holdsworth S.R., et al. Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria. Front. Immunol. 2022;13:821595. doi: 10.3389/fimmu.2022.821595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.821595</ArticleId><ArticleId IdType="pmc">PMC8829141</ArticleId><ArticleId IdType="pubmed">35154139</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S., Ashok G., Debroy R., Ramaiah S., Livingstone P., Anbarasu A. Impact of the COVID-19 Pandemic on Routine Vaccine Landscape: A Global Perspective. Hum. Vaccines Immunother. 2023;19:2199656. doi: 10.1080/21645515.2023.2199656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2199656</ArticleId><ArticleId IdType="pmc">PMC10294763</ArticleId><ArticleId IdType="pubmed">37078597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A., Undurraga E.A., Zubizarreta J.R., González C., Acevedo J., Pizarro A., Vergara V., Soto-Marchant M., Gilabert R., Flores J.C., et al. Effectiveness of CoronaVac in Children 3–5 Years of Age during the SARS-CoV-2 Omicron Outbreak in Chile. Nat. Med. 2022;28:1377–1380. doi: 10.1038/s41591-022-01874-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01874-4</ArticleId><ArticleId IdType="pmc">PMC9307483</ArticleId><ArticleId IdType="pubmed">35605637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A., Undurraga E.A., Flores J.C., Zubizarreta J.R., González C., Pizarro A., Ortuño-Borroto D., Acevedo J., Leo K., Paredes F., et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study. Lancet Reg. Health. 2023;21:100487. doi: 10.1016/j.lana.2023.100487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100487</ArticleId><ArticleId IdType="pmc">PMC10117174</ArticleId><ArticleId IdType="pubmed">37155483</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Clapham H.E., Tan A.T., Chia W.N., Tham C.Y.L., Lim J.M., Kunasegaran K., Tan L.W.L., Dutertre C.A., Shankar N., et al. Highly Functional Virus-Specific Cellular Immune Response in Asymptomatic SARS-CoV-2 Infection. J. Exp. Med. 2021;218:e20202617. doi: 10.1084/jem.20202617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202617</ArticleId><ArticleId IdType="pmc">PMC7927662</ArticleId><ArticleId IdType="pubmed">33646265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>